Zobrazeno 1 - 10
of 38
pro vyhledávání: ''
Autor:
Hope S. Rugo, Elene Viscosi, Gayle C. Blouin, Aditya Bardia, Jennifer Hutchinson, Colin D. Weekes, Beverly Moy, Erika Nakajima, Laura Spring
Publikováno v:
Oncologist
Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate that contains the irinotecan active metabolite, SN-38, linked to a humanized monoclonal antibody targeting tr
Autor:
Hope S. Rugo, Stephen Chia, Wei-Chun Hsu, Juan Pablo Zarate, Hemanth Kanakamedala, David Chandiwana, Chu-Ling Yu, Jinhee Park, Antonia Ridolfi, Stuart J. Turner
Publikováno v:
The Oncologist
Background The BYLieve trial (NCT03056755) confirmed efficacy and safety of alpelisib with fulvestrant for hormone receptor–positive (HR+), human epidermal growth factor receptor‐2–negative (HER2−), PIK3CA‐mutated advanced breast cancer (AB
Autor:
Florian Scotté, Luigi Celio, Yolanda Escobar, Alessandra Franceschetti, Karin Jordan, Danielle Bell, Matti Aapro, Richard Berman
Publikováno v:
Oncologist
Background Guideline-recommended antiemetic prophylaxis improves nausea and vomiting control in most patients undergoing chemotherapy. Multinational Association of Supportive Care in Cancer/European Society for Medical Oncology (MASCC/ESMO) antiemeti
Autor:
Edward C. Stites, Steven C. Plaxe, Thomas McFall, Ramez N. Eskander, Kasey Bamel, Sadakatsu Ikeda, Barbara A. Parker, Shumei Kato, Razelle Kurzrock, Kenta Takahashi
Publikováno v:
The Oncologist
We report on a woman with aggressive estrogen receptor‐positive, KRAS‐mutated ovarian cancer who achieved a remarkable response to combination therapy with the MEK inhibitor (trametinib) and the aromatase inhibitor (letrozole), even though the di
Autor:
William L. Bailey, Kathryn J. Ruddy, Lee S. Schwartzberg, Rebecca Clark-Snow, Thomas W. LeBlanc, Eric Roeland, Rudolph M. Navari, Luke M. Schmerold, Ryan D. Nipp, Ravi Potluri, Eros Papademetriou, Gary Binder
Publikováno v:
Oncologist
Purpose Chemotherapy-induced nausea and vomiting (CINV) contributes to avoidable acute care, a metric now tracked in Medicare's oncology outcome measure. CINV is preventable, yet guidelines are often not followed. We sought to quantify acute care inv
Autor:
Jimin Chen, Rongjie Tao, Ye Gao, Huan Chen, Henghui Zhang, Dandan Liang, Yongsheng Gao, Yong Wang, Rui Fan
Publikováno v:
Oncologist
We describe a case of recurrent glioblastoma treated with anlotinib in this report. The patient was administered anlotinib 12 mg p.o. once every day (days 1–14, with a 21-day cycle) (anlotinib clinical study NCT04004975) and oral temozolomide chemo
Autor:
Cathy Yi Xia, Anthony J. Gill, Michael E. Buckland, Stephen B. Fox, Amanda L. Hudson, Mark Li, Helen Westman, Bob T. Li, Stephen Clarke, Vivek Rathi, Michael Boyer, Viive M. Howell, Sarah A. Hayes, Heng Wei, Brandon Lau, Wendy A Cooper, Malinda Itchins, Michael Rodriguez, Nick Pavlakis
Publikováno v:
Oncologist
Since its discovery in 2007, we have seen the lives of patients diagnosed with advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancers (NSCLC) transform with the advent of molecular therapies with first-, second-, and third-g
Autor:
Ajay K. Kakkar, Rodney Hughes, Mark Levine, Anna Falanga, Rupert Bauersachs, Alex Kahney, John Wong, Gloria Kayani
Publikováno v:
The Oncologist
Background Fundamental Research in Oncology and Thrombosis (FRONTLINE) is a global survey of physicians' perceptions and practice in the management of venous thromboembolism (VTE) in patients with cancer. Materials and Methods The present survey, FRO
Autor:
Giada Rizzi, Lee S. Schwartzberg, Rebecca Clark-Snow, Ekaterine Arkania, Richard J. Gralla, Rudolph M. Navari, Matti Aapro, Daniel Voisin, Rita Wickham, Irena Radyukova, Kamal Patel, Eric Roeland
Publikováno v:
The Oncologist
Background NEPA, a combination antiemetic of a neurokinin‐1 (NK1) receptor antagonist (RA) (netupitant [oral]/fosnetupitant [intravenous; IV]) and 5‐HT3RA, palonosetron] offers 5‐day CINV prevention with a single dose. Fosnetupitant solution co
Autor:
Toshinobu Hayashi, Mototsugu Shimokawa, Keisuke Aiba, Hitoshi Kawazoe, Kazuo Tamura, Toshiaki Saeki, Hirotoshi Iihara
Publikováno v:
The Oncologist
Background We previously reported the results of a prospective study of chemotherapy‐induced nausea and vomiting (CINV) in a cohort of patients who received carboplatin‐based chemotherapy and were selected from a nationwide registry of those sche